CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Perspective Therapeutics, Inc. (CATX) is rated D (1.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C); its weakest is Revisions (F). The rating has held at D for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C (2.2) | D+ (1.6) | D (1.3) | D+ (1.6) | F (0.0) | D (1.3) |
| 2026-11-04 | C+ (2.6) | D (1.3) | D (1.2) | D (1.4) | F (0.0) | D (1.3) |
| 2026-10-28 | C (2.4) | D (1.3) | D (1.2) | D (1.3) | F (0.0) | D (1.2) |
| 2026-10-21 | F (0.2) | D (1.2) | D (1.2) | D+ (1.7) | C+ (2.6) | D (1.4) |
| 2026-10-14 | F (0.2) | D (1.2) | D (1.2) | D+ (1.7) | C+ (2.6) | D (1.4) |